Compare Dr. Reddys with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ASTRAZENECA PHARMA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ASTRAZENECA PHARMA DR. REDDYS LAB/
ASTRAZENECA PHARMA
 
P/E (TTM) x 40.3 127.0 31.8% View Chart
P/BV x 5.5 38.9 14.2% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 DR. REDDYS LAB   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-20
ASTRAZENECA PHARMA
Mar-18
DR. REDDYS LAB/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3631,278 263.1%   
Low Rs2,352883 266.5%   
Sales per share (Unadj.) Rs1,054.2228.4 461.5%  
Earnings per share (Unadj.) Rs121.910.4 1,176.4%  
Cash flow per share (Unadj.) Rs190.216.3 1,169.8%  
Dividends per share (Unadj.) Rs25.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs938.798.8 950.4%  
Shares outstanding (eoy) m166.1725.00 664.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.74.7 57.3%   
Avg P/E ratio x23.4104.2 22.5%  
P/CF ratio (eoy) x15.066.4 22.6%  
Price / Book Value ratio x3.010.9 27.8%  
Dividend payout %20.50-   
Avg Mkt Cap Rs m474,83127,008 1,758.1%   
No. of employees `00021.71.4 1,596.6%   
Total wages/salary Rs m33,8021,535 2,201.7%   
Avg. sales/employee Rs Th8,091.04,210.9 192.1%   
Avg. wages/employee Rs Th1,561.31,132.2 137.9%   
Avg. net profit/employee Rs Th935.8191.1 489.7%   
INCOME DATA
Net Sales Rs m175,1705,710 3,067.8%  
Other income Rs m6,206123 5,066.1%   
Total revenues Rs m181,3765,833 3,109.7%   
Gross profit Rs m24,421463 5,275.7%  
Depreciation Rs m11,348147 7,698.8%   
Interest Rs m9830-   
Profit before tax Rs m18,296438 4,177.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m5610-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,403179 -784.2%   
Profit after tax Rs m20,260259 7,819.4%  
Gross profit margin %13.98.1 172.0%  
Effective tax rate %-7.740.8 -18.8%   
Net profit margin %11.64.5 254.9%  
BALANCE SHEET DATA
Current assets Rs m125,9913,209 3,925.9%   
Current liabilities Rs m72,1412,070 3,485.9%   
Net working cap to sales %30.720.0 154.0%  
Current ratio x1.71.6 112.6%  
Inventory Days Days7372 101.0%  
Debtors Days Days10535 300.0%  
Net fixed assets Rs m83,854790 10,610.4%   
Share capital Rs m83150 1,662.0%   
"Free" reserves Rs m155,1572,419 6,413.3%   
Net worth Rs m155,9882,469 6,317.1%   
Long term debt Rs m1,3040-   
Total assets Rs m232,2534,605 5,043.1%  
Interest coverage x19.6NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.81.2 60.8%   
Return on assets %9.15.6 162.6%  
Return on equity %13.010.5 123.8%  
Return on capital %12.617.7 71.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m84,193300 28,106.5%   
Fx outflow Rs m39,6162,015 1,966.1%   
Net fx Rs m44,577-1,715 -2,598.7%   
CASH FLOW
From Operations Rs m29,84188 33,948.8%  
From Investments Rs m-4,923-94 5,259.6%  
From Financial Activity Rs m-25,159NA-  
Net Cashflow Rs m-266-6 4,666.7%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.4 0.3 1,800.0%  
FIIs % 35.3 15.7 224.8%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 9.1 168.1%  
Shareholders   75,885 12,856 590.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   JUBILANT PHARMOVA   PANACEA BIOTECH  WOCKHARDT  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Worst Sector in the Market(Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


May 14, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS